Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

Principal Investigator: Switzer, Benjamin J

A Phase II Study of Type-1 Polarized Dendritic Cell (αDC1) -based Treatment in
Combination with Tumor-Selective Chemokine Modulation (CKM: Interferon alpha-2b,
Rintatolimod and Celecoxib) in Melanoma Patients with Primary PD-1/PD-L1 Resistance

Principal Investigator: Puzanov, Igor

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors

Principal Investigator: Puzanov, Igor

S2015: Melanoma Margins Trial (MelMart): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1CM V 2CM Wide Excision Margins for Primary Cutaneous Melanoma

Principal Investigator: O'Brien, Shalana B